Our press releases and latest news

Cannamedical® Pharma GmbH, the leading independent brand in Germany’s fast-growing medical cannabis market, announced today the first closing of a new 12M€ strategic investment round and the addition of Steve Wiggins to the Company’s Board of Directors. Mr. Wiggins is one of the most successful American healthcare entrepreneurs, with a long history of starting and building businesses that have become leaders in their health sectors. The Company will use this investment capital for key strategic growth initiatives including domestic and European expansion to promote its market-leading product portfolio.

Cannamedical® has combined world class quality products, a uniquely effective market access strategy and a laser-focus on customer service, uniting industry leading medical, quality assurance and healthcare specialists in the effort to help providers and pharmacists provide important medicine to patients. In addition, the Company has built the most advanced supply chain in the European medical cannabis sector, with its supplier network consisting of numerous partners on three continents. This approach has enabled the Company to provide world class product quality, selection and stability, and to drive continued strong growth, even in times of uncertainty such as the current situation.

“Cannamedical® attracted me because of their young, mission-driven leadership team and their commitment to product quality. I believe the human endocannabinoid system holds a key to addressing a wide range of diseases and conditions. Cannamedical® is a unique business and has a generational opportunity. I am excited and honored to be part of their journey as a Board Director and investor”, said Steve Wiggins.

“I am proud of the hard work of every member of the Cannamedical® team. Through their passion, we are in a stronger position than ever to build Cannamedical® as a leader in the European medical cannabis industry” said David Henn, founder and CEO of Cannamedical® Pharma. “With his decades of experience helping develop new markets for medical solutions, Steve is a perfect fit as an investor and Board Director.”

Mr. Wiggins has over 30 years of experience launching and managing healthcare companies and has founded nine healthcare companies including Oxford Health Plans, which grew into a Fortune 300 company under his leadership. Most recently, Steve built Remedy Partners into the world’s largest bundled payment network, with current throughput in excess of $7 billion. Steve was also a Managing Director of Essex Woodlands Health Ventures, one of the oldest and largest U.S. healthcare venture capital and growth equity firms. He presently manages a family office, making investments globally in the health care industry.

With the addition of Mr. Wiggins, Cannamedical’s® Board of Directors now consists of Mr. Wiggins, Mr. Henn, Jesse Du Bey of Orkila Capital and Fabian Thylmann of SN-Invests.

Press contact

Sandra Grußbach
presse@cannamedical.de

About Cannamedical®

Cannamedical® is the leading independent specialty pharmaceutical cannabis products Company in Europe. We believe that the human endocannabinoid system holds the key to providing millions of patients with wellness solutions and are committed to bring the best Cannamedical®-branded products to patients, providers and pharmacists to increase quality of life.Cannamedical® focuses on helping patients with chronic illnesses by importing and processing only the highest-quality medicinal cannabis products and by supplying ~2,500 pharmacies and clinical facilities. In addition to providing medicinal cannabis products of the highest standards, Cannamedical® focuses on providing critical information to medical and customer service professionals. Our production partners worldwide comply with the highest pharmaceutical quality standards – the EU-GMP guidelines (European Good Manufacturing Practice). As a GDP-certified (Good Distribution Practice) company, Cannamedical’s® entire supply chain is guaranteed, from the agricultural environment all the way to the pharmacy. Cannamedical® Pharma GmbH was founded in 2016 and employs approximately 50 employees in Cologne. In addition, Cannamedical® operates subsidiaries in Canada and the UK. For more information, visit www.cannamedical.com.

Cologne, 23st Jan 2020 – Last Friday, Cannamedical® Pharma GmbH, the German pioneer and one of the leading independent medical cannabis suppliers in Europe, initiated a Medical Advisory Board bringing together important stakeholders and experts in the field.

This meeting held under the title of “Medicinal cannabis – Options and new perspectives for the patient”, was an exchange between the Medical Affairs Team of Cannamedical® and leading experts in medicinal cannabis treatment. Medical/scientific as well as pharmacoeconomic aspects were discussed and initial premises for achievement of communal goals were identified.

“It is our aim to identify gaps in evidence and to close these gaps communally via close collaboration with physicians, health insurance companies, professional associations and political representatives.“ With the following words, Prof. Dr. Kirsten Müller-Vahl summarized the result-oriented approach. “Evidence requires time and in the meantime we need good interim solutions.“

Cannamedical® Pharma was able to attract a first class advisory board involving university professors and other experts from various fields of specialization such as pain therapy and neurology as well as a representative from a public health insurance company.

According to Dr. Thomas Baur, Chief Commercial Officer of Cannamedical® Pharma “The discussion about chances and limits of treatment with medicinal cannabis as well as the current experiences of patients, physicians and health insurance providers yielded valuable ideas and conclusions which clearly confirm our commitment to extend and sponsor collaboration with experts from clinical practice and science.“ Prof. Dr. Dr. Joachim Nadstawek emphasized the current situation of patients: “It is still a major challenge for patients to find an experienced cannabis prescribing doctor.“  

Cannamedical® will continue to strive for easier access to medicinal cannabis treatment for severely ill patients and to support members of the relevant specialist groups by supplying comprehensive and well researched information.

Press contact

Sandra Grußbach
E-Mail: presse@cannamedical.de
Phone: +49 221 999 852 51

About Cannamedical^® Pharma GmbH

We at Cannamedical^® Pharma GmbH are committed to helping doctors, medical specialists and pharmacists to improve their patients’ quality of life. The top-class products by Cannamedical concentrate on helping people with chronic illnesses to lead the best possible life with medicinal cannabis. To this end, we import and process only high-quality medicinal cannabis products and supply them to around 2,500 pharmacies and clinical facilities.
As well as the provision of top-class medicinal cannabis products, our focus is on training medical professionals, and providing sector-leading customer service. Our production partners worldwide must comply with the highest pharmaceutical quality standards – the so-called GMP guidelines (Good Manufacturing Practice). With its quality management, Cannamedical guarantees the highest product standards. We ourselves are GDP-certified (Good Distribution Practice), in other words, our entire supply chain is guaranteed, from the agricultural environment to the pharmacy. Cannamedical^® Pharma GmbH was founded in Cologne in 2016 and employs more than 50 staff. In addition, Cannamedical operates subsidiaries in Canada and the UK.

For more information, visit www.cannamedical.com.

Cologne 19 December 2019– Cannamedical® Pharma GmbH, one of the leading cannabis distributors and supplier of one of the best-known medical Cannabis brands in Germany and the European Union, is now offering a GMP-certified kit for the formulation of pharmaceutical CBD-oils. With this formulation kit, Cannamedical® enables pharmacists to prepare prescription CBD oils for various indications, such as chronic inflammatory diseases, anxiety disorders and psychoses, and to provide patients with medication according to the NRF, an official German Guideline for Pharmacies describing the formulation of prescription medicines.

“Since the European Commission decided in January 2019 to include CBD in the Novel Food Regulation, the availability of CBD products has been restricted. Patients have been looking for a source for CBD oil, which is now available in pharmaceutical quality,”says David Henn, CEO and founder of Cannamedical Pharma GmbH.“This is the second important market entry for us in 2019, and we will start offering THC extracts in Europe next year in addition to the Cannamedical® Cannabis Flowers and the CDB formulation kit, which is now available.”

The formulation kit includes all components required for the preparation of up to six or three bottles with 5% or 10% CBD-oil, respectively.

The promising therapeutic option of the CBD formulation kit complements the existing product portfolio of Cannamedical® currently comprising Indica, Sativa, Hybrid, and CBD-rich Cannabis flowers, each variant in four different potencies.

Press contact

Sandra Grußbach
E-Mail: presse@cannamedical.de
Phone: +49 221 999 852 51

About Cannamedical^® Pharma GmbH

We at Cannamedical^® Pharma GmbH are committed to helping doctors, medical specialists and pharmacists to improve their patients’ quality of life. The top-class products by Cannamedical concentrate on helping people with chronic illnesses to lead the best possible life with medicinal cannabis. To this end, we import and process only high-quality medicinal cannabis products and supply them to around 2,500 pharmacies and clinical facilities.
As well as the provision of top-class medicinal cannabis products, our focus is on training medical professionals, and providing sector-leading customer service. Our production partners worldwide must comply with the highest pharmaceutical quality standards – the so-called GMP guidelines (Good Manufacturing Practice). With its quality management, Cannamedical guarantees the highest product standards. We ourselves are GDP-certified (Good Distribution Practice), in other words, our entire supply chain is guaranteed, from the agricultural environment to the pharmacy. Cannamedical^® Pharma GmbH was founded in Cologne in 2016 and employs more than 50 staff. In addition, Cannamedical operates subsidiaries in Canada and the UK.

For more information, visit www.cannamedical.com.

Cologne, September 9th, 2019 – On September 9th, Cannamedical^® Pharma GmbH, a leading cannabis distributor and one of the best-known medicinal cannabis brands in Germany and the European Union, imported from Portugal to Germany, the largest quantity of medicinal cannabis ever transported within the European Union.

“The European market is clearly developing its ability to grow and ship world-class medicinal cannabis products, which is an important step in the development of the EU medicinal cannabis market, which we believe will be the world’s largest. Cannamedical continues to demonstrate that our approach as the leading independent importer of finding the best products in all supply markets to serve to our patients can establish milestones within the industry,” says David Henn, CEO of Cannamedical. “We are proud of the contribution we are making to provide a stable supply of medicinal cannabis to patients in Germany and thankful for our world-class supply partners.”

Once the packaging process is complete, the imported Cannamedical product is expected to be available to patients beginning in mid-October. Cannamedical continues to be the only independent medicinal cannabis importer to successfully distribute products under its own brand name in Germany.

With this import, Cannamedical continues to expand its global network of suppliers within the cannabis industry. Cannamedical announced in May 2019 that it had entered into three international supply agreements with suppliers of medicinal cannabis flowers and extracts and has since initiated two additional EU-GMP certifications for supplier partners. The company currently holds a total of 9 supply agreements with partners across three continents.

Cannamedical Pharma GmbH is the largest independent importer and distributor of medicinal cannabis in Germany. Cannamedical was founded by David Henn in November 2016 and its 50+ employees are based in Cologne. In early 2019, Cannamedical raised €15M from New York and Hamburg-based investment firm Orkila Capital. The company recently expanded its management team with the addition of Chief Commercial Officer, Dr. Thomas Baur and Head of Quality Assurance, Dr. Ralf Bradenahl.

Press contact

Sandra Grußbach
E-Mail: presse@cannamedical.de
Phone: +49 221 999 852 51

About Cannamedical^® Pharma GmbH

We at Cannamedical^® Pharma GmbH are committed to helping doctors, medical specialists and pharmacists to improve their patients’ quality of life. The top-class products by Cannamedical concentrate on helping people with chronic illnesses to lead the best possible life with medicinal cannabis. To this end, we import and process only high-quality medicinal cannabis products and supply them to around 2,500 pharmacies and clinical facilities.
As well as the provision of top-class medicinal cannabis products, our focus is on training medical professionals, and providing sector-leading customer service. Our production partners worldwide must comply with the highest pharmaceutical quality standards – the so-called GMP guidelines (Good Manufacturing Practice). With its quality management, Cannamedical guarantees the highest product standards. We ourselves are GDP-certified (Good Distribution Practice), in other words, our entire supply chain is guaranteed, from the agricultural environment to the pharmacy. Cannamedical^® Pharma GmbH was founded in Cologne in 2016 and employs more than 50 staff. In addition, Cannamedical operates subsidiaries in Canada and the UK.

For more information, visit www.cannamedical.com.

Photo David Henn, CEO Cannamedical® Pharma GmbH available at:
https://cannamedical.de/foto-david-henn

Photo of the shipment available at:
https://cannamedical.de/foto_import_charterflug

Cologne, 4 September 2019 – Cannamedical^® Pharma GmbH, one of the best-known medicinal cannabis companies in Germany and the European Union, is expanding its management team with experienced experts from the pharmaceutical industry. The independent importer and wholesaler has named Dr. med. Thomas Baur as Chief Commercial Officer (CCO). With immediate effect, the 41-year-old will be responsible for the areas of Medical Affairs, Marketing, Pharmacy and Field Sales, with a focus on providing professional advice and support to doctors, pharmacies and health insurers, as well as the expansion of the sales network.

“In Dr. Thomas Baur we have decided to employ one top expert. With his experience and industry knowledge we will strengthen our quality assurance and the expansion of the Cannamedical brand. Together we shall continue to extend our advantage as the largest and best-known independent importer of medicinal cannabis, and secure our success in Germany and the EU in the long term,” says David Henn, CEO and founder of Cannamedical.

For the last 15 years, Baur has held management positions in healthcare companies such as Fresenius, Medtronic and Grünenthal, specialising in pain therapy. Most recently, Baur’s responsibilities included commercial assessment and business development, and he was head of the business unit for the hospital business in the DACH region.

“I am delighted to be part of the Cannamedical team. Cannamedical already offers leading products and services to physicians and pharmacists, in order to enable patients to lead a life worth living. Our clear objective is to further extend our leading position in the market, and to redefine the quality of consultation provided to doctors, pharmacies and health insurers. Together we want to adapt new approaches to treatment and provide innovative therapy options in the form of medicinal cannabis to patients with various illnesses,” says Dr. Thomas Baur, CCO Cannamedical.

Founded in November 2016 by David Henn, Cannamedical is now the largest independent importer and wholesaler of medicinal cannabis in Germany. Based in Cologne, since commencing operations in 2017, Cannamedical now has more than 50 employees.

Press contact

Sandra Grußbach
E-Mail: presse@cannamedical.de
Phone: +49 221 999 852 51

About Cannamedical^® Pharma GmbH

We at Cannamedical^® Pharma GmbH are committed to helping doctors, medical specialists and pharmacists to improve their patients’ quality of life. The top-class products by Cannamedical concentrate on helping people with chronic illnesses to lead the best possible life with medicinal cannabis. To this end, we import and process only high-quality medicinal cannabis products and supply them to around 2,500 pharmacies and clinical facilities.
As well as the provision of top-class medicinal cannabis products, our focus is on training medical professionals, and providing sector-leading customer service. Our production partners worldwide must comply with the highest pharmaceutical quality standards – the so-called GMP guidelines (Good Manufacturing Practice). With its quality management, Cannamedical guarantees the highest product standards. We ourselves are GDP-certified (Good Distribution Practice), in other words, our entire supply chain is guaranteed, from the agricultural environment to the pharmacy. Cannamedical^® Pharma GmbH was founded in Cologne in 2016 and employs more than 50 staff. In addition, Cannamedical operates subsidiaries in Canada and the UK.

For more information, visit www.cannamedical.com.

Cologne, Germany, 29 January 2019 – Cannamedical^® Pharma GmbH, one of the leading independent cannabis wholesalers in Germany and the European Union, has received a 15-million-euro equity investment from the US- and Germany-based growth equity investment firm Orkila Capital LLC. As a result of its investment, Orkila Capital has acquired a minority in Cannamedical.

“I am very pleased that Orkila Capital has recognized our growth potential and chosen to invest in us. Our most important goal is to ensure the timely supply of medicinal cannabis to patients at all times. And we are very proud of our reputation in Germany for providing the highest levels of customer service and operating with transparency and integrity. Today we help doctors, healthcare professionals and pharmacists in Germany and other European countries to improve the quality of their patients’ lives. Our products are focused on helping people with cancer, multiple sclerosis (MS) and chronic or acute pain to live their best life with medical cannabis” commented David Henn, CEO and founder of Cannamedical^® Pharma GmbH.

Cannamedical^®’s commitment is aimed at safety, reliability and a quality management system that guarantees the highest possible product standards. All production partners must also meet the highest pharmaceutical quality standards worldwide – the so-called GMP guidelines (Good Manufacturing Practice).

Jesse Du Bey, founder and Managing Partner of Orkila Capital, says: “We look for leading platforms in massive and evolving consumer markets and have found such an opportunity in Cannamedical^®. As with our early leading investments in the global health and wellness space and the European craft beer industry, we believe in Cannamedical^®’s ability to provide customers with an innovate product and help develop the potential of a huge market. Having observed the development of the North American medical cannabis market, we know medical cannabis is an important, organic medicine with few side effects, primarily targeting patients with acute and chronic conditions. Having witnessed the terrible consequences of the opiate prescription wave in the US, we believe Cannamedical^® can be a key player in helping German healthcare professionals provide millions of consumers with a natural therapy for chronic pain and many other acute conditions.”

Orkila Capital’s Series A investment in Cannamedical^® is the largest private equity transaction in the cannabis industry in Europe. Following Orkila Capital’s investment, founder David Henn holds approximately 60 percent of the shares in Cannamedical^® Pharma GmbH. SN-Invests, a Luxembourg-based start-up investor, is the company’s third largest shareholder with a stake of almost 21 percent.

Currently, around 60,000 patients in Germany have a license to use medical cannabis. Independent research and comparison with data from other countries shows that up to three percent of the population could benefit from treatment with medicinal cannabis, which could equate to up to approximately 2.5 million patients in Germany. For the EU as a whole, the patient population could eventually equate to approximately 15 million patients.

Cannamedical^® Pharma GmbH was founded in 2016 and started operating following the legalization of medical cannabis in Germany in March 2017. Today, the Company employs around 40 employees in Cologne and generates a million turnover.

Press contact
Kristina Quade
Email: presse[at]cannamedical.de
Phone: +49 221 999 852 57

About Cannamedical^® Pharma GmbH

We at Cannamedical^® Pharma GmbH are committed to helping doctors, healthcare professionals and pharmacists to improve the quality of their patients’ lives. Cannamedical^®’s products are focused on helping people with cancer, multiple sclerosis (MS) and chronic or acute pain to live their best life with medical cannabis. To this end, we import high-quality medical cannabis products and distribute them to around 2,000 pharmacies and clinical facilities.
In addition to the medical care of patients, our focus is on education within the professional framework and the satisfaction of our customers. Our commitment is aimed at safety, reliability and a quality management system that guarantees the highest possible product standards. Our production partners must also meet the highest pharmaceutical quality standards worldwide – the so-called GMP guidelines (Good Manufacturing Practice). We ourselves are GDP (Good Distribution Practice) certified, meaning that our products are of the highest quality during manufacture and our entire supply chain is guaranteed, right up to the pharmacy delivery. Cannamedical^® Pharma GmbH was founded in 2016 and employs around 40 people in Cologne. Cannamedical also has subsidiaries in Canada, the United Kingdom and Greece.
For more information visit cannamedical.com.

About Orkila Capital LLC

Orkila Capital LLC (“Orkila”) was formed in 2013 to pursue proprietary and compelling growth equity investment opportunities in the consumer, media and entertainment sectors.
Orkila invests in leading companies at the forefront of evolving market opportunities, including Mikkeller, Recognition Media (The Webby Awards), Omnipollo and Bellator MMA. Additionally, the Principals of Orkila co-founded Crash Line Productions (Boston Calling Music Festival) as well as sourced and helped execute the IRONMAN investment on behalf of their prior firm.
With over 20 years of experience, the principals of Orkila seek to leverage their deep industry knowledge and relationships to focus on growth platforms with differentiated brands, IP, assets or content. Orkila manages approximately $200 million of capital across two private equity funds.
For more information visit orkilacapital.com.